Kiadis Pharma presents at the EBMT in Göteborg
Oncology focused biotech company Kiadis Pharma is very pleased to announce the Satellite Symposium on its lead product ATIR™ at the 35th Annual Meeting of the European Group for Blood and Marrow Transplantation in Göteborg, Sweden on Sunday, March 29, 2009.
At this Satellite Symposium: “Improving the outcomes of matched and mismatched transplants by selective allodepletion of T-cells”, data will be presented from the company’s ongoing clinical studies on ATIR™ by its principal investigators. Furthermore the background of the recently submitted Registration Trial on ATIR will for the first time be presented to this audience.
Please look here for more information regarding the Satellite Symposium and the programme of the EBMT.
More news
- Kiadis Pharma signs license agreement with Hospira to commercialize ATIR™ in Europe and Asia - Partnership would advance innovative stem cell transplant product 4-1-2011
- Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 8-7-2010
- Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-4-2010
- Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™ 29-11-2009
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting 5-11-2009
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium 8-4-2009
- Kiadis Pharma presents at the EBMT in Göteborg 31-3-2009
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting 6-2-2009
- Kiadis Pharma appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer 6-1-2009
- Kiadis Pharma announces appointment of Mark Skaletsky to its Supervisory Board 11-12-2008
